#United States #Redwood City #Galvanize Therapeutics #Sofinnova Partners #PEF Technology

Groundbreaking Funding for Cancer and Lung Disease Treatment

Galvanize Therapeutics, Inc., a medical technology company based in Redwood City, California, has successfully secured $100 million in an oversubscribed Series C financing round. This substantial capital injection is poised to elevate the company's mission of transforming treatment options for cancer and chronic lung diseases. The funding round was led by Sofinnova Partners, a renowned venture capital firm specializing in life sciences, in collaboration with an impressive lineup of global investors including Norwest Venture Partners, Elevage Medical Technologies, and Janus Henderson Investors.

The funds raised will primarily be directed towards expanding Galvanize's commercial footprint and advancing clinical endeavors related to its innovative Aliya® PEF (Pulsed Electric Field) therapy designed for solid tumors and RheOx®, a therapy targeting chronic bronchitis, a leading contributor to chronic obstructive pulmonary disease (COPD). This non-pharmacologic intervention leverages short-duration, focused electrical pulses aimed at destabilizing pathological cellular processes, thereby offering a novel approach to combat these serious health issues.

As part of the company's strategic growth, Doug Godshall has been appointed as the Chairman and CEO. Formerly the CEO of Shockwave Medical, Godshall is optimistic about the potential of Galvanize's technologies. He stated, “My enthusiasm for Galvanize has grown as our team pushes forward in our initial commercial strategies. The Aliya and RheOx technologies are promising in their fields, catering to millions of patients who have limited options in current pharmaceutical approaches.” This sentiment highlights the urgent need for innovative solutions in medical treatment, particularly for diseases that affect many but are inadequately addressed by existing therapies.

In conjunction with the financing, additional key players were integrated into Galvanize's Board of Directors, including Antoine Papiernik, Chairman and Managing Partner at Sofinnova Partners, who remarked on the unique potential he and his firm see in Galvanize's technology. “We see the PEF program as a game-changer for patients facing serious unmet medical needs,” he noted. This collaborative push hints at a solid future for Galvanize, as they combine resources and expertise from various sectors to maximize therapeutic advancements.

Galvanize's PEF platform utilizes innovative applications of electrical fields to disrupt harmful cellular activities without the adverse effects associated with traditional drug therapies. As the company continues to develop its therapies, there is growing anticipation about their impact on both oncology and chronic respiratory conditions.

Looking Ahead

With the successful acquisition of funding and a dynamic leadership team in place, Galvanize Therapeutics is on an upward trajectory towards better treatment outcomes for patients suffering from chronic illnesses. The financial support not only enhances their operational capabilities but also underscores the confidence investors have in their vision and technology.

For more information about Galvanize Therapeutics and their pioneering work, visit their official website at galvanizetx.com. This comprehensive approach could mark a significant milestone in how chronic diseases are treated in the future, advocating for a move beyond conventional pharmaceutical solutions.

As they pave the way for innovative treatments, Galvanize is positioning itself to be a leader in the healthcare technology landscape, potentially setting new standards in patient care and management.